AbbVie: 5 Reasons That Make A Buy Case

You’re always faced with the choice: do you want to win often, or win big? Every trade pushes you to pick between the comfort of frequent small wins and the patience it takes to land those larger, less common profits. Getting a grip on how win rate and risk/reward ratio affect your results helps you…

Bank of America Corp DE grew its position in shares of Ares Capital Co. (NASDAQ:ARCC – Free Report) by 12.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,951,926 shares of the inves Source link

Last week I wrote about Gold Guardian making +27% while gold went crazy. Alpha Pulse AI? Almost nothing. A handful of trades. Minimal activity. Someone asked me: “Is something wrong with your AI EA?” No. Something is exactly right. The Contrast Same week. Same gold market. Two completely different approaches. Gold Guardian: 8 trades, 8…

I’m happy to announce DivGro’s 57th Home Run!  When a stock in my portfolio doubles my original investment in total return, I assign it Home Run status.  As a dividend growth investor, I invest in high-quality dividend growth stocks with long histories of increasing annual dividend payouts.  Unless the underlying fundamentals change, there’s rarely a reason to sell these…

The path to bankruptcy and financial chaos is well signposted and well-trod. The Big Man did not discover it. He merely stayed on it. Federal debt held by the public will increase by 9% to 11% by 2034, according to a Congressional Budget Office memo on the budget bill. Debt service costs will rise by…

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) insider Todd Franklin Watanabe sold 1,500 shares of the company’s stock in a transaction on Monday, March 24th. The stock was sold at an average price of $17.52, for a total value of $26,280.00. Following the sale, the insider now owns 927,414 shares of the company’s stock,…